Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In Ho Song

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Brain : a Journal of Neurology|April 19, 2002
A newly identified chromosomal microdeletion and an N-box mutation of the AChR epsilon gene cause a congenital myasthenic syndromeAngela Abicht, Rolf Stucka, Carolin Schmidt, et al.
Oncology Reports|July 5, 2014
Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinomaJunhye Kwon, Hyeon-Joon Yoon, Ji-Hee Kim, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
Annals of the Rheumatic Diseases|August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient responseRoy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
Annals of the Rheumatic Diseases|June 28, 2012
Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRIChristian E Althoff, Joachim Sieper, In-Ho Song, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
Cells|October 31, 2018
PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma ModelsTae Sup Lee, In Ho Song, Jong Il Shin, et al.
Rheumatology (Oxford, England)|August 26, 2022
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPAREEduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, et al.
Cells|June 2, 2021
TSPO Expression Modulatory Effect of Acetylcholinesterase Inhibitor in the Ischemic Stroke Rat ModelYoo Sung Song, Sang Hee Lee, Jae Ho Jung, et al.
Seminars in Arthritis and Rheumatism|November 1, 2015
Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trialIn-Ho Song, Kay-Geert Hermann, Hildrun Haibel, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Brain : a Journal of Neurology|April 19, 2002
A newly identified chromosomal microdeletion and an N-box mutation of the AChR epsilon gene cause a congenital myasthenic syndromeAngela Abicht, Rolf Stucka, Carolin Schmidt, et al.
Oncology Reports|July 5, 2014
Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinomaJunhye Kwon, Hyeon-Joon Yoon, Ji-Hee Kim, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
Annals of the Rheumatic Diseases|August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient responseRoy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
Annals of the Rheumatic Diseases|June 28, 2012
Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRIChristian E Althoff, Joachim Sieper, In-Ho Song, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
Cells|October 31, 2018
PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma ModelsTae Sup Lee, In Ho Song, Jong Il Shin, et al.
Rheumatology (Oxford, England)|August 26, 2022
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPAREEduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, et al.
Cells|June 2, 2021
TSPO Expression Modulatory Effect of Acetylcholinesterase Inhibitor in the Ischemic Stroke Rat ModelYoo Sung Song, Sang Hee Lee, Jae Ho Jung, et al.
Seminars in Arthritis and Rheumatism|November 1, 2015
Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trialIn-Ho Song, Kay-Geert Hermann, Hildrun Haibel, et al.
Pageof 11